IntelGenx Technologies Corp. is focused on the development and manufacturing of thin oral film pharmaceutical products. However, they have recently entered the non-prescription cannabis market. In addition, on March 15, IGX announced it will partner with atai Life Sciences to develop compounds for the prevention or treatment of mental-health disorders, including compounds that have psychedelic properties. PayPal co-founder Peter Thiel is an investor in atai. Meanwhile, since March 30, four IntelGenx insiders have bought a combined total of 90,000 shares at an average price of 57 cents.
stock
Ted Dixon is CEO of INK Research which provides insider news and knowledge to investors. For more background on insider reporting in Canada, visit the FAQ section at www.inkresearch.com. Securities referenced in this profile may have already appeared in recent reports distributed to INK subscribers. INK staff may also hold a position in profiled securities.
Chart reflects public-market transactions of common shares or unit trusts by company officers and directors.
Be smart with your money. Get the latest investing insights delivered right to your inbox three times a week, with the Globe Investor newsletter. Sign up today.